These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

748 related articles for article (PubMed ID: 32197277)

  • 41. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
    Sinning D; Landmesser U
    Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies.
    Brandts J; Ray KK
    Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inclisiran for the treatment of dyslipidemia.
    Nishikido T; Ray KK
    Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia.
    Wang X; Qiu M; Cheng Z; Ji X; Chen J; Zhu H; Tang Y; Huang Z; Su G; Wang G; Huang Z; Yao Z; Lin J; Sun Y; Li S; Shao C; Zhao Y; Bai X; Han Y
    J Am Heart Assoc; 2024 Jun; 13(11):e033669. PubMed ID: 38818934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
    Schwartz GG; Steg PG; Szarek M; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Pordy R; Quintero K; Roe MT; Sasiela WJ; Tamby JF; Tricoci P; White HD; Zeiher AM;
    N Engl J Med; 2018 Nov; 379(22):2097-2107. PubMed ID: 30403574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia.
    Khan SA; Naz A; Qamar Masood M; Shah R
    Am J Cardiol; 2020 Nov; 134():69-73. PubMed ID: 32892993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
    Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS
    J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel therapies for familial hypercholesterolemia.
    Mohamed F; Seedat F; Raal FJ
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
    Hovingh GK; Lepor NE; Kallend D; Stoekenbroek RM; Wijngaard PLJ; Raal FJ
    Circulation; 2020 Jun; 141(22):1829-1831. PubMed ID: 32479195
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inclisiran: How Widely and When Should We Use It?
    Pirillo A; Catapano AL
    Curr Atheroscler Rep; 2022 Oct; 24(10):803-811. PubMed ID: 35877035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.
    Tomlinson B; Patil NG; Fok M; Lam CWK
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):279-295. PubMed ID: 33866776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
    Hopkins PN; Krempf M; Bruckert E; Donahue S; Yang F; Zhang Y; DiCioccio AT
    J Clin Lipidol; 2019; 13(6):970-978. PubMed ID: 31767518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An update on inclisiran for the treatment of elevated LDL cholesterol.
    Barkas F; Ray K
    Expert Opin Pharmacother; 2024 Mar; 25(4):349-358. PubMed ID: 38549399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
    N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pharmacological and clinical profile of inclisiran sodium, a long-acting LDL cholesterol lowering siRNA, LEQVIO for s.c. injection syringe 300 ‍mg].
    Mikami T; Fujiwara Y; Akahori M; Tomimatsu N; Tamaki Y
    Nihon Yakurigaku Zasshi; 2024; 159(4):254-263. PubMed ID: 38945909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.